← All trials
NCT03281655
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2020
- Primary completion
- Mar 31, 2024
- Completion date
- May 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MessinaLead sponsor
- University of AthensCollaborator
- University of MessinaReponsible party - principal investigator
- University of MessinaOverall official - principal investigator
- University of VictoriaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.